Steward Partners Investment Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14K | Hold |
649
| – | – | ﹤0.01% | 3057 |
|
|
2025
Q1 | $10.8K | Hold |
649
| – | – | ﹤0.01% | 3059 |
|
|
2024
Q4 | $11.9K | Buy |
649
+199
| +44% | +$3.65K | ﹤0.01% | 3028 |
|
|
2024
Q3 | $6.92K | Hold |
450
| – | – | ﹤0.01% | 3088 |
|
|
2024
Q2 | $7.31K | Hold |
450
| – | – | ﹤0.01% | 2920 |
|
|
2024
Q1 | $8.32K | Hold |
450
| – | – | ﹤0.01% | 2878 |
|
|
2023
Q4 | $14.1K | Hold |
450
| – | – | ﹤0.01% | 2561 |
|
|
2023
Q3 | $9.38K | Sell |
450
-117
| -21% | -$2.44K | ﹤0.01% | 2623 |
|
|
2023
Q2 | $13.6K | Buy |
567
+467
| +467% | +$11.2K | ﹤0.01% | 2466 |
|
|
2023
Q1 | $1.88K | Hold |
100
| – | – | ﹤0.01% | 3031 |
|
|
2022
Q4 | $1.59K | Hold |
100
| – | – | ﹤0.01% | 3063 |
|
|
2022
Q3 | $2K | Hold |
100
| – | – | ﹤0.01% | 2994 |
|
|
2022
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 3076 |
|
|
2022
Q1 | $2K | Hold |
100
| – | – | ﹤0.01% | 3061 |
|
|
2021
Q4 | $2K | Hold |
100
| – | – | ﹤0.01% | 2995 |
|
|
2021
Q3 | $2K | Hold |
100
| – | – | ﹤0.01% | 2965 |
|
|
2021
Q2 | $2K | Sell |
100
-7,270
| -99% | -$145K | ﹤0.01% | 6845 |
|
|
2021
Q1 | $190K | Buy |
7,370
+7,195
| +4,111% | +$186K | ﹤0.01% | 1332 |
|
|
2020
Q4 | $9K | Hold |
175
| – | – | ﹤0.01% | 2337 |
|
|
2020
Q3 | $7K | Buy |
175
+100
| +133% | +$4K | ﹤0.01% | 2241 |
|
|
2020
Q2 | $4K | Hold |
75
| – | – | ﹤0.01% | 2303 |
|
|
2020
Q1 | $3K | Buy |
+75
| New | +$3K | ﹤0.01% | 2189 |
|
|
2019
Q3 | – | Sell |
-1,600
| Closed | -$42K | – | 2605 |
|
|
2019
Q2 | $42K | Buy |
+1,600
| New | +$42K | ﹤0.01% | 1397 |
|
|
2018
Q4 | – | Sell |
-2,600
| Closed | -$54K | – | 785 |
|
|
2018
Q3 | $54K | Sell |
2,600
-4,300
| -62% | -$89.3K | ﹤0.01% | 1170 |
|
|
2018
Q2 | $105K | Sell |
6,900
-100
| -1% | -$1.52K | 0.01% | 828 |
|
|
2018
Q1 | $157K | Buy |
7,000
+350
| +5% | +$7.85K | 0.01% | 661 |
|
|
2017
Q4 | $200K | Buy |
+6,650
| New | +$200K | 0.02% | 518 |
|